Meanwhile, the present study supports the findings of recent large clinical trials recommending that GIK administration be started as early as possible (namely, before a rapid increase in insulin resistance) [7, 11, 31, 32] and underscores the importance of preventing or ameliorating insulin resistance as an acute-phase treatment of ACS to ensure the effective utilization of the intrinsic GIK cascade activation. The gene discussed is INS; the disease is Insulin resistance.